Castle Biosciences completed the acquisition of Myriad myPath® Melanoma from Myriad Genetics for $32.5m.

Castle Biosciences, a biotechnology company, completed the acquisition of Myriad myPath® Melanoma, a laboratory offering the myPath Melanoma test, from Myriad Genetics, a genetic testing and precision medicine company, for $32.5m.